ClosedPublished 27 Apr 2023

Biosynex SA /
Chembio Diagnostics, Inc.

Biosynex SA completes Chembio Diagnostics acquisition

Price
$17.2m
Stage
Closed
Buy side: Biosynex SA
Buy sideBiosynex SA
Target: Chembio Diagnostics, Inc.
TargetChembio Diagnostics, Inc.
Source · 27 Apr 2023
Buy side: Biosynex SA
Buy sideBiosynex SA
Target: Chembio Diagnostics, Inc.
TargetChembio Diagnostics, Inc.
01 / BuyerBiosynex SA
02 / TargetChembio Diagnostics, Inc.
01

What happened

Biosynex SA completed its acquisition of Chembio Diagnostics, Inc. on April 27, 2023, making Chembio a wholly-owned indirect subsidiary of Biosynex.

The consideration was $0.45 per share in cash, for a transaction value of approximately $17.2 million. Chembio focuses on point-of-care diagnostics for infectious diseases.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Biosynex SA completes Chembio Diagnostics acquisition

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    The source this page is built from.

  2. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.